Literature DB >> 6097270

Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine.

P Hajdú, D Schmidt, M Bomm, L Hack, A Keller.   

Abstract

A highly sensitive and specific enzymatic assay for the quantitative determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product Hoe 498-diacid in serum and a GLC method for the simultaneous determination of both compounds in urine are described. Both methods involve extraction from the respective biological fluid using disposable C 18 columns. In serum, the enzyme-inhibiting properties of Hoe 498-diacid (Hoe 498 can readily be converted to its hydrolysis product) are utilized for the determination of both compounds concurrently. The serum extract is dissolved in buffer solution and incubated with human serum as angiotensin converting enzyme (peptidyl-dipeptide-hydrolase, EC 3.4.15.1) source and hip-his-leu substrate. The hippuric acid liberated is quantitated by HPLC. The urine extract is treated with diazomethane followed by trifluoroacetic anhydride to convert Hoe 498 and Hoe 498-diacid to their methylester, trifluoroacetyl derivatives, which are then determined simultaneously by GLC using a nitrogen specific detector.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097270

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.

Authors:  P U Witte; R Irmisch; P Hajdú; H Metzger
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.

Authors:  J P Bussien; J Nussberger; M Porchet; B Waeber; H R Brunner; M Perisic; M J Tansey; M Bomm; P Hajdu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

3.  Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

Authors:  T M MacDonald; K Craig; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

Review 4.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.

Authors:  B Beermann; O Nyquist; C Höglund; K A Jacobsson; U Näslund; M Jensen-Urstad
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.

Authors:  P J Manhem; S G Ball; J J Morton; G D Murray; B J Leckie; R Fraser; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of ramipril.

Authors:  S Meisel; A Shamiss; T Rosenthal
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.